Attention-deficit/hyperactivity disorder

Синдром дефицита внимания с гиперактивностью
Stephen V. Faraone, Luís Augusto Rohde, Jan K. Buitelaar, Tobias Banaschewski, Joseph Biederman, Barbara Franke, Philip Asherson, Josep Antoni Ramos‐Quiroga, Edmund Sonuga‐Barke, Rosemary Tannock
2015-08-05

attention-deficit/hyperactivity disorderevidence-based treatmentneurocognitive impairmentneurodevelopmental disorderpsychiatric comorbidity
Attention-deficit/hyperactivity disorder (ADHD) is a persistent neurodevelopmental disorder that affects 5% of children and adolescents and 2.5% of adults worldwide. Throughout an individual's lifetime, ADHD can increase the risk of other psychiatric disorders, educational and occupational failure, accidents, criminality, social disability and addictions. No single risk factor is necessary or sufficient to cause ADHD. In most cases ADHD arises from several genetic and environmental risk factors that each have a small individual effect and act together to increase susceptibility. The multifactorial causation of ADHD is consistent with the heterogeneity of the disorder, which is shown by its extensive psychiatric co-morbidity, its multiple domains of neurocognitive impairment and the wide range of structural and functional brain anomalies associated with it. The diagnosis of ADHD is reliable and valid when evaluated with standard criteria for psychiatric disorders. Rating scales and clinical interviews facilitate diagnosis and aid screening. The expression of symptoms varies as a function of patient developmental stage and social and academic contexts. Although there are no curative treatments for ADHD, evidenced-based treatments can markedly reduce its symptoms and associated impairments. For example, medications are efficacious and normally well tolerated, and various non-pharmacological approaches are also valuable. Ongoing clinical and neurobiological research holds the promise of advancing diagnostic and therapeutic approaches to ADHD. For an illustrated summary of this Primer, visit: http://go.nature.com/J6jiwl.
1
ADHD is a persistent neurodevelopmental disorder affecting approximately 5% of children and adolescents and 2.5% of adults worldwide.
2
ADHD typically results from multiple genetic and environmental risk factors, each exerting small effects that jointly increase susceptibility.
3
Evidence-based treatments, including medications and non-pharmacological approaches, can substantially reduce ADHD symptoms and associated impairments, although no curative treatment exists.
4
Standard psychiatric diagnostic criteria provide reliable and valid ADHD diagnosis, supported by rating scales and clinical interviews.
5
The disorder is heterogeneous, involving substantial psychiatric comorbidity, diverse neurocognitive impairments, and varied structural and functional brain anomalies.

Attention-deficit/hyperactivity disorder (ADHD)

The multifactorial causes, clinical heterogeneity, diagnosis, symptom expression, associated impairments, and treatment of ADHD

Publication Details
Publication Date
2015-08-05
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Stephen V. Faraone
Luís Augusto Rohde
Jan K. Buitelaar
Tobias Banaschewski
Joseph Biederman
Barbara Franke
Philip Asherson
Josep Antoni Ramos‐Quiroga
Edmund Sonuga‐Barke
Rosemary Tannock
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%